Phase 3 Transthyretin Amyloidosis Clinical Trials

3 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–3 of 3 trials

Recruiting

Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals1,250 enrolled207 locationsNCT07052903

Recruiting

Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

CardiomyopathiesAmyloidosisHeart Diseases+3 more

Eidos Therapeutics, a BridgeBio company582 enrolled98 locationsNCT06563895

Recruiting

Phase 3

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Intellia Therapeutics1,200 enrolled132 locationsNCT06128629